News Breaks |
|
|
| January 9, 2013 |
| 17:45 EDT |  | TEVA, BIIB | Teva files FDA petition to review safety of Biogen MS drug, Reuters reports
Teva (TEVA) has filed a petition with the FDA that asks the agency to have an outside panel evaluate the safety of Biogen's (BIIB) multiple sclerosis drug, BG-12, before approval, and if the FDA review is granted the drug's launch could be delayed, according to a Reuters report. Reference Link |
|
|
News For TEVA;BIIB From The Last 14 Days Check below for free stories on TEVA;BIIB the last two weeks. |
|
|
| May 23, 2013 |
| 08:04 EDT |  | BIIB | Biogen appoints Spyros Artavanis-Tsakonas as Chief Scientific Officer
 Subscribe for More Information |
|
| May 22, 2013 |
| 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
Subscribe for More Information |
|
| May 21, 2013 |
| 07:24 EDT |  | BIIB | Global Health Care to host a conference
Subscribe for More Information |
|
| 05:44 EDT | | BIIB | Biogen submits application to FDA for approval of Plegridy in RMS
Subscribe for More Information |
|
| May 20, 2013 |
| 15:57 EDT |  | BIIB | Biogen IMS numbers should not be adjusted down at ISI Group
ISI Group confirmed with Biogen that Tecfidera is not captured by IMS and numbers should not be adjusted downward to reflect free drugs dispensed. |
|
| 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 07:39 EDT | | BIIB | Biogen weekly MS drug scripts up 26.5%, says Citigroup
Citigroup says weekly scripts for Biogen's multiple sclerosis drug Tecfidera were up 26.5% to 1,621. Citi says the launch of Tecfidera is on track to beat Q2 estimates by a wide margin and it keeps a Buy rating on shares of Biogen. |
|
| May 16, 2013 |
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 14, 2013 |
| 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. |
|
| May 13, 2013 |
| 11:12 EDT | | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information |
| |
| 09:44 EDT | | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:49 EDT | | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT |  | TEVA | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
| 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. |
|
|
|
|
|
